Trial Outcomes & Findings for UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT NCT02222688)

NCT ID: NCT02222688

Last Updated: 2020-08-13

Results Overview

The MTD is defined as the highest dose studied at which no more than one in six patients experience a dose-limiting toxicity (DLT) during the DLT observation period. The biologically active dose will be determined at a dose below or equal to the MTD upon review of the the study data; the final determination will also consider any cumulative or delayed toxicity.

• Recruitment status: COMPLETED
• Study phase: PHASE1
• Target enrollment: 26 participants
• Primary outcome timeframe: 1 year
• Results posted on: 2020-08-13

Participant Flow

Subjects were enrolled into the study between August 2014 and September 2017 and included patients seen in the UCSD Health system.

Twenty-seven subjects were treated with cirmtuzumab and are included in the primary outcome analysis. One subject was enrolled into the trial twice; first in Cohort 1 and then again in Cohort 4 and is counted once for reporting of the baseline characteristics.

Participant milestones

Measure	Cirmtuzumab 0.015 - 0.03 mg/kg Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cimrtuzumab 2.0 - 4.0 mg/kg Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
Overall Study STARTED	4	3	3	5	3	3	6
Overall Study COMPLETED	3	3	3	3	2	3	5
Overall Study NOT COMPLETED	1	0	0	2	1	0	1

Reasons for withdrawal

Measure	Cirmtuzumab 0.015 - 0.03 mg/kg Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cimrtuzumab 2.0 - 4.0 mg/kg Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
Overall Study Withdrawal by Subject	0	0	0	2	1	0	1
Overall Study Disease progression	1	0	0	0	0	0	0

Baseline Characteristics

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

Baseline characteristics by cohort

Measure	Cirmtuzumab 0.015 - 0.03 mg/kg n=4 Participants Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg n=3 Participants Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg n=3 Participants Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cirmtuzumab 2.0 - 4.0 mg/kg n=5 Participants Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg n=3 Participants Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg n=3 Participants Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg n=6 Participants Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)	Total n=27 Participants Total of all reporting groups
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants
Race (NIH/OMB) White	4 Participants n=5 Participants	3 Participants n=7 Participants	2 Participants n=5 Participants	5 Participants n=4 Participants	3 Participants n=21 Participants	2 Participants n=8 Participants	6 Participants n=8 Participants	25 Participants n=24 Participants
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants
Age, Categorical Between 18 and 65 years	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	1 Participants n=8 Participants	5 Participants n=24 Participants
Age, Categorical >=65 years	4 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants	4 Participants n=4 Participants	3 Participants n=21 Participants	2 Participants n=8 Participants	5 Participants n=8 Participants	22 Participants n=24 Participants
Age, Continuous	72.75 years STANDARD_DEVIATION 1.5 • n=5 Participants	70.67 years STANDARD_DEVIATION 11.68 • n=7 Participants	66.67 years STANDARD_DEVIATION 3.51 • n=5 Participants	69.4 years STANDARD_DEVIATION 7.23 • n=4 Participants	70 years STANDARD_DEVIATION 2.65 • n=21 Participants	71.67 years STANDARD_DEVIATION 9.29 • n=8 Participants	77.33 years STANDARD_DEVIATION 8.78 • n=8 Participants	71.81 years STANDARD_DEVIATION 7.32 • n=24 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	3 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	4 Participants n=8 Participants	13 Participants n=24 Participants
Sex: Female, Male Male	2 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=8 Participants	2 Participants n=8 Participants	14 Participants n=24 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	4 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	5 Participants n=4 Participants	3 Participants n=21 Participants	3 Participants n=8 Participants	6 Participants n=8 Participants	27 Participants n=24 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	1 Participants n=24 Participants
Region of Enrollment United States	4 participants n=5 Participants	3 participants n=7 Participants	3 participants n=5 Participants	5 participants n=4 Participants	3 participants n=21 Participants	3 participants n=8 Participants	6 participants n=8 Participants	27 participants n=24 Participants

PRIMARY outcome

Timeframe: 1 year

The MTD is defined as the highest dose studied at which no more than one in six patients experience a dose-limiting toxicity (DLT) during the DLT observation period. The biologically active dose will be determined at a dose below or equal to the MTD upon review of the the study data; the final determination will also consider any cumulative or delayed toxicity.

Outcome measures

Measure	All Participants n=27 Participants All participants who received any treatment with cirmtuzumab	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cirmtuzumab 2.0 - 4.0 mg/kg Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
Maximum Tolerated Dose (MTD) or Biologically Active Dose of Cirmtuzumab	20 mg/kg	—	—	—	—	—	—

PRIMARY outcome

Timeframe: The DLT observation period is 56 days from the start of the first infusion for the intra-patient dosing cohorts and 28 days after the start of the first infusion for subsequent dosing cohorts

The occurrence of any of the following adverse events considered to be possibly, probably, or definitely related to cirmtuzumab within the DLT observation period (56 days from the first infusion for cohorts with intrapatient dose escalation, and 28 days of the start investigational treatment for cohorts without intrapatient dose escalation):

1. Grade 3 or greater non-hematologic toxicity with the exception of Grade 3 infusion reaction.

2. Grade 4 neutropenia lasting more than 5 days despite appropriate medical management.

3. Grade 4 thrombocytopenia or grade 3 thrombocytopenia with bleeding or any requirement for platelets transfusion.

4. Grade 3 or greater febrile neutropenia (temperature ≥ 38.5ºC).

5. Grade 4 anemia unexplained by underlying disease.

6. Any AE requiring a dose delay of greater than 14 days.

7. Patients with baseline cytopenias or starting blood counts in the grade 2 range are evaluable for hematologic DLT.

Outcome measures

Measure	All Participants n=4 Participants All participants who received any treatment with cirmtuzumab	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg n=3 Participants Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg n=3 Participants Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cirmtuzumab 2.0 - 4.0 mg/kg n=5 Participants Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg n=3 Participants Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg n=3 Participants Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg n=6 Participants Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
Rate of Dose Limiting Toxicities (DLTs)	0 Occurrence of DLTs	0 Occurrence of DLTs	0 Occurrence of DLTs	0 Occurrence of DLTs	0 Occurrence of DLTs	0 Occurrence of DLTs	0 Occurrence of DLTs

SECONDARY outcome

Timeframe: From the start of investigational treatment to completion of follow-up, an average of 33 weeks

Treatment emergent adverse events (description, timing, CTCAE grade, severity, seriousness, and relatedness)

Outcome measures

Measure	All Participants n=4 Participants All participants who received any treatment with cirmtuzumab	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg n=3 Participants Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg n=3 Participants Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cirmtuzumab 2.0 - 4.0 mg/kg n=5 Participants Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg n=3 Participants Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg n=3 Participants Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg n=6 Participants Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
Safety and Tolerability of UC-961 by Ongoing Evaluation of AEs.	20 Treatment emergent AEs	37 Treatment emergent AEs	15 Treatment emergent AEs	31 Treatment emergent AEs	17 Treatment emergent AEs	34 Treatment emergent AEs	46 Treatment emergent AEs

SECONDARY outcome

Timeframe: From baseline visit to response assessment visit at 56 days after final cirmtuzumab infusion, an average of 52 days

Population: Evaluable subjects or those who completed 4 cycles of cirmtuzumab

Clinical response [stable disease (SD) or progressive disease (PD)] defined by iwCLL criteria including clinical, hematological, and bone marrow features for a period of at least 2 months from completion of therapy

Outcome measures

Measure	All Participants n=3 Participants All participants who received any treatment with cirmtuzumab	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg n=3 Participants Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg n=3 Participants Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cirmtuzumab 2.0 - 4.0 mg/kg n=3 Participants Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg n=2 Participants Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg n=3 Participants Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg n=5 Participants Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
Clinical Activity Determined by the International Working Group in CLL (iwCLL) Criteria Stable Disease	0 participants	0 participants	1 participants	0 participants	1 participants	1 participants	2 participants
Clinical Activity Determined by the International Working Group in CLL (iwCLL) Criteria Progressive Disease	3 participants	3 participants	2 participants	3 participants	1 participants	2 participants	3 participants

SECONDARY outcome

Timeframe: From start of treatment until objective tumor progression or death

The duration of time from the start of study treatment until objective tumor progression or death

Outcome measures

Measure	All Participants n=4 Participants All participants who received any treatment with cirmtuzumab	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg n=3 Participants Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg n=3 Participants Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cirmtuzumab 2.0 - 4.0 mg/kg n=5 Participants Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg n=3 Participants Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg n=3 Participants Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg n=6 Participants Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
Progression Free Survival as Determined by iwCLL Criteria	29.5 Weeks Interval 2.0 to 79.9	27.6 Weeks Interval 10.5 to 54.2	24.5 Weeks Interval 18.5 to 32.0	36.6 Weeks Interval 1.0 to 136.0	25.4 Weeks Interval 4.0 to 42.2	26.2 Weeks Interval 20.5 to 29.0	19.9 Weeks Interval 5.2 to 56.3

Adverse Events

Cirmtuzumab 0.015 - 0.03 mg/kg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Cirmtuzumab 0.5 - 1.0 mg/kg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Cimrtuzumab 2.0 - 4.0 mg/kg

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

Cirmtuzumab 8 mg/kg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Cirmtuzumab 16 mg/kg

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

Cirmtuzumab 20 mg/kg

Serious events: 2 serious events

Other events: 6 other events

Deaths: 0 deaths

Serious adverse events

Measure	Cirmtuzumab 0.015 - 0.03 mg/kg n=4 participants at risk Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg n=3 participants at risk Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg n=3 participants at risk Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cimrtuzumab 2.0 - 4.0 mg/kg n=5 participants at risk Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg n=3 participants at risk Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg n=3 participants at risk Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg n=6 participants at risk Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
Skin and subcutaneous tissue disorders Skin infection	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Gastrointestinal disorders	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Respiratory, thoracic and mediastinal disorders Lung infection	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.

Other adverse events

Measure	Cirmtuzumab 0.015 - 0.03 mg/kg n=4 participants at risk Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion	Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg n=3 participants at risk Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 0.5 - 1.0 mg/kg n=3 participants at risk Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion	Cimrtuzumab 2.0 - 4.0 mg/kg n=5 participants at risk Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion	Cirmtuzumab 8 mg/kg n=3 participants at risk Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion	Cirmtuzumab 16 mg/kg n=3 participants at risk Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion	Cirmtuzumab 20 mg/kg n=6 participants at risk Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
Blood and lymphatic system disorders Anemia	100.0% 4/4 • Number of events 6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	100.0% 3/3 • Number of events 12 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	100.0% 3/3 • Number of events 9 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	60.0% 3/5 • Number of events 9 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	100.0% 3/3 • Number of events 10 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	100.0% 3/3 • Number of events 14 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 4/6 • Number of events 10 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Cardiac disorders Atrial fibrillation	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Cardiac disorders Atrial flutter	25.0% 1/4 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Cardiac disorders Chest pain - cardiac	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Cardiac disorders Palpitations	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Cardiac disorders Sinus bradycardia	25.0% 1/4 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Ear and labyrinth disorders Ear and labyrinth disorders - other	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Ear and labyrinth disorders External ear pain	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Eye disorders Conjunctivitis	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Eye disorders Eye disorders - other	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Eye disorders Floater	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Abdominal pain	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Bloating	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Constipation	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	50.0% 3/6 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Diarrhea	25.0% 1/4 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	100.0% 3/3 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	40.0% 2/5 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Dry mouth	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Dyspepsia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Fecal incontinence	25.0% 1/4 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Gastrointestinal reflux disease	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Gastrointestinal disorders - other	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Nausea	25.0% 1/4 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	40.0% 2/5 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Gastrointestinal disorders Vomiting	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
General disorders Chills	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
General disorders Fatigue	50.0% 2/4 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 2/6 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
General disorders Fever	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
General disorders Flu-like symptoms	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
General disorders Non-cardiac chest pain	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Infections and infestations Bronchial infection	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Infections and infestations Lung infection	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Infections and infestations Mucosal infection	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Infections and infestations Papulopustular rash	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Infections and infestations Sepsis	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Infections and infestations Sinusitis	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Infections and infestations Skin infection	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Infections and infestations Upper respiratory infection	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 2/6 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Infections and infestations Urinary tract infection	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Injury, poisoning and procedural complications Bruising	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Investigations Alanine aminotransferase increased	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Investigations Aspartate aminotransferase increased	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Investigations Blood bilirubin increased	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Investigations Creatinine increased	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Investigations Lipase increased	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	100.0% 3/3 • Number of events 6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Investigations Serum amylase increased	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Investigations Weight loss	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Metabolism and nutrition disorders Anorexia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Investigations Thrombocytopenia	100.0% 4/4 • Number of events 13 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 9 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	80.0% 4/5 • Number of events 8 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	100.0% 3/3 • Number of events 5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 7 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 11 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Investigations Neutropenia	25.0% 1/4 • Number of events 4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 7 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	40.0% 2/5 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 10 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Metabolism and nutrition disorders Hyperglycemia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Metabolism and nutrition disorders Hyperkalemia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Metabolism and nutrition disorders Hypernatremia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Metabolism and nutrition disorders Hyperuricemia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 2/6 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Metabolism and nutrition disorders Hypokalemia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Musculoskeletal and connective tissue disorders Arthritis	25.0% 1/4 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Nervous system disorders Akathisia	25.0% 1/4 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Nervous system disorders Dizziness	50.0% 2/4 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Nervous system disorders Headache	25.0% 1/4 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	40.0% 2/5 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 2/6 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Nervous system disorders Parasthesia	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Nervous system disorders Sinus pain	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Nervous system disorders Transient ischemic attacks	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Psychiatric disorders Confusion	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Psychiatric disorders Depression	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Psychiatric disorders Insomnia	50.0% 2/4 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Psychiatric disorders Restlessness	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Renal and urinary disorders Cystitis noninfective	25.0% 1/4 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Renal and urinary disorders Urinary frequency	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Renal and urinary disorders Urinary urgency	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Renal and urinary disorders Urine discoloration	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Reproductive system and breast disorders Breast pain	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	50.0% 3/6 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	66.7% 2/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Respiratory, thoracic and mediastinal disorders Hoarseness	25.0% 1/4 • Number of events 3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	16.7% 1/6 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Skin and subcutaneous tissue disorders Skin induration	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Vascular disorders Flushing	0.00% 0/4 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	33.3% 1/3 • Number of events 2 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	20.0% 1/5 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.
Vascular disorders Hot flashes	25.0% 1/4 • Number of events 1 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/5 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/3 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.	0.00% 0/6 • Adverse events collected from the start of the first infusion of cirmtuzumab to the last subject's final visit in long-term follow-up (on average 3 years 8 months) Note that some patients elected to enroll in extension study (ClinicalTrails.gov record #NCT02860676) and therefor the cut-off date for some may be the date patient was first treated on extension protocol. Timeframe for this result therefore difficult to reconcile as asked to report here. Note no deaths observed during the timeframe of the study observation period.

Additional Information

Thomas Kipps, MD, PhD

University of California, San Diego

Phone: 858-534-5400

Email: tkipps@ucsd.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place